Nilotinib US FDA Label
- Compound: 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
- Description: Nilotinib is a member of (trifluoromethyl)benzenes, a member of pyrimidines, a member of pyridines, a member of imidazoles, a secondary amino compound and a secondary carboxamide. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and an anticoronaviral agent.
- Brand Name:
- Code(s): AMN107
- Approved:
- Kinase Class: NRY
- Inhibitor Type: IIA
- Literature (PubMed): 0
- Target(s): ABL proto-oncogene 1, non-receptor tyrosine kinase , discoidin domain receptor tyrosine kinase 1 , Platelet derived growth factor receptor alpha , Platelet derived growth factor receptor beta
- Disease(s): chronic myeloid leukemia